At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.

The U. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’ therapy for a ‌rare form of obesity caused by ...

First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

Rhythm Pharmaceuticals (RYTM) added ~8% in the premarket on Friday after the U.S. Food and Drug Administration (FDA) approved a label expansion for its lead asset, setmelanotide, to allow its use in ...

Rhythm Pharmaceuticals received Food and Drug Administration approval for an expanded indication for setmelanotide, its treatment for acquired hypothalamic obesity. Acquired hypothalamic obesity is a ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) shares rose 11% Friday morning following FDA approval of IMCIVREE (setmelanotide) for patients with acquired hypothalamic obesity. The approval marks the first and ...

Collaborating with scientists from New York, Toronto, and Tokyo, Harvard Stem Cell Institute (HSCI) researchers have devised two methods for using stem cells to generate the type of neurons that help ...

LAS VEGAS -- Obese patients who continue to have "thyroid symptoms" even when their levels are normalized may have a hypothalamic dysfunction, researchers reported here. In a single-center study of 50 ...

The prevalence of obesity is steadily rising and has huge health and financial implications for society. Weight gain is due to an imbalance between dietary intake and energy expenditure and research ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was linked to reduction in BMI at 52 weeks compared with placebo for patients with acquired ...